BR112021020523A2 - Comprimidos de canabinoide de desintegração rápida - Google Patents

Comprimidos de canabinoide de desintegração rápida

Info

Publication number
BR112021020523A2
BR112021020523A2 BR112021020523A BR112021020523A BR112021020523A2 BR 112021020523 A2 BR112021020523 A2 BR 112021020523A2 BR 112021020523 A BR112021020523 A BR 112021020523A BR 112021020523 A BR112021020523 A BR 112021020523A BR 112021020523 A2 BR112021020523 A2 BR 112021020523A2
Authority
BR
Brazil
Prior art keywords
tablet
cannabinoid
composition
fast disintegrating
tablets
Prior art date
Application number
BR112021020523A
Other languages
English (en)
Portuguese (pt)
Inventor
Provstgaard Nielsen Bruno
Schackinger Boesen Dorte
Ziegler Bruun Heidi
Original Assignee
Nordiccan As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA3040513A external-priority patent/CA3040513C/en
Priority claimed from CA3040547A external-priority patent/CA3040547C/en
Priority claimed from CA3040532A external-priority patent/CA3040532C/en
Priority claimed from US16/386,477 external-priority patent/US10925853B2/en
Priority claimed from CA3065042A external-priority patent/CA3065042C/en
Priority claimed from US16/713,580 external-priority patent/US11633351B2/en
Application filed by Nordiccan As filed Critical Nordiccan As
Publication of BR112021020523A2 publication Critical patent/BR112021020523A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
BR112021020523A 2019-04-17 2020-04-17 Comprimidos de canabinoide de desintegração rápida BR112021020523A2 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CA3040513A CA3040513C (en) 2019-04-17 2019-04-17 An oral cannabinoid tablet
CA3040547A CA3040547C (en) 2019-04-17 2019-04-17 Cannabinoid lozenge formulation
CA3040532A CA3040532C (en) 2019-04-17 2019-04-17 Lozenge for improved delivery of cannabinoids
US16/386,477 US10925853B2 (en) 2019-04-17 2019-04-17 Oral cannabinoid tablet
CA3065042A CA3065042C (en) 2019-12-13 2019-12-13 Fast disintegrating cannabinoid tablets
US16/713,580 US11633351B2 (en) 2019-12-13 2019-12-13 Fast disintegrating cannabinoid tablets
PCT/DK2020/050102 WO2020211915A1 (en) 2019-04-17 2020-04-17 Fast disintegrating cannabinoid tablets

Publications (1)

Publication Number Publication Date
BR112021020523A2 true BR112021020523A2 (pt) 2021-12-07

Family

ID=70802555

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021020523A BR112021020523A2 (pt) 2019-04-17 2020-04-17 Comprimidos de canabinoide de desintegração rápida

Country Status (12)

Country Link
EP (2) EP4268815A3 (cg-RX-API-DMAC10.html)
JP (1) JP7556882B2 (cg-RX-API-DMAC10.html)
CN (1) CN113784704A (cg-RX-API-DMAC10.html)
AU (1) AU2020258631B2 (cg-RX-API-DMAC10.html)
BR (1) BR112021020523A2 (cg-RX-API-DMAC10.html)
DK (1) DK3920891T3 (cg-RX-API-DMAC10.html)
ES (1) ES2975266T3 (cg-RX-API-DMAC10.html)
FI (1) FI3920891T3 (cg-RX-API-DMAC10.html)
MX (1) MX2021012712A (cg-RX-API-DMAC10.html)
PL (1) PL3920891T3 (cg-RX-API-DMAC10.html)
WO (1) WO2020211915A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202107389B (cg-RX-API-DMAC10.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020412501A1 (en) * 2019-12-24 2022-08-18 Cannadol Pharmaceuticals Ltd Compositions comprising terpenes and their use in the treatment or alleviation of pain or anxiety
TWI923583B (zh) * 2020-04-14 2026-05-01 美商健生生物科技公司 包含胺基嘧啶衍生物或其醫藥上可接受之鹽之用於經口投予之醫藥組成物
LT4243797T (lt) * 2020-11-16 2026-06-10 Orcosa Inc. Greitos infuzijos platforma ir kompozicijos, skirtos žmonių terapiniam gydymui
US11672761B2 (en) * 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
CN114748429A (zh) * 2020-12-29 2022-07-15 汉义生物科技(北京)有限公司 一种水溶性大麻素制剂及其制备方法
JP2023010677A (ja) * 2021-07-09 2023-01-20 株式会社東洋新薬 固形組成物
JP2023010676A (ja) * 2021-07-09 2023-01-20 株式会社東洋新薬 固形組成物
US20240415853A1 (en) * 2023-03-21 2024-12-19 Fertin Pharma A/S Cannabinoid Self-Emulsifying Systems
JP2025529608A (ja) * 2023-07-24 2025-09-09 ポビバ コーポレーション てんかんを処置する為の組成物及び方法
DK202330231A1 (en) * 2023-09-27 2025-04-10 Fertin Pharma As Cannabidiol for alleviating xerostomia
CN118021744A (zh) * 2024-02-05 2024-05-14 谛邈生物科技(北京)有限公司 一种大麻二酚型大麻素化合物冻干闪释片及其制备方法
DK202430722A1 (en) * 2024-11-25 2026-06-09 Fertin Pharma As Sugar free soft chew tablets

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1361864T3 (en) * 2001-02-14 2014-03-03 Gw Pharma Ltd FLYLDENDE SPRAY FORMULATIONS FOR buccal administration of cannabinoids
GB0320854D0 (en) * 2003-09-05 2003-10-08 Arrow No 7 Ltd Buccal drug delivery
CA2664315C (en) * 2006-09-15 2016-01-19 Echo Pharmaceuticals B.V. Dosage unit for sublingual, buccal or oral administration of water-insoluble pharmaceutically active substances
EP2164462B1 (de) * 2007-06-06 2017-05-31 Basf Se Pharmazeutische formulierung für die herstellung von schnell zerfallenden tabletten
US20090004248A1 (en) * 2007-06-29 2009-01-01 Frank Bunick Dual portion dosage lozenge form
US9023322B2 (en) * 2008-03-26 2015-05-05 Stichting Sanammad Chewing gum compositions comprising cannabinoids
WO2009151072A1 (ja) * 2008-06-13 2009-12-17 大日本住友製薬株式会社 口腔内速崩壊錠及びその製造方法
KR20130076015A (ko) * 2011-12-28 2013-07-08 주식회사 삼양바이오팜 높은 경도를 갖는 속붕정 및 이의 제조 방법
EP2609912A1 (en) * 2011-12-30 2013-07-03 Deva Holding Anonim Sirketi Pharmaceutical combination of fingolimod and nabiximols
CA2845443A1 (en) * 2014-03-04 2015-09-04 Pharmascience Inc. Orally disintegrating tablet of nabilone and method of manufacturing
CA2992923C (en) * 2014-07-21 2021-06-29 Pharmaceutical Productions, Inc. Solid dosage form composition for buccal and sublingual administration of cannabinoids
WO2016092539A1 (en) * 2014-12-07 2016-06-16 One World Cannabis Ltd Use of cannabis to treat migraine
EP3253368A4 (en) * 2015-02-02 2018-08-22 Axim Biotechnologies, Inc. Cannabinoid and sugar alcohol complex, methods to make and use
US10765658B2 (en) * 2016-06-22 2020-09-08 Mastix LLC Oral compositions delivering therapeutically effective amounts of cannabinoids
KR20220132674A (ko) * 2016-08-03 2022-09-30 젤리라 테라퓨틱스 오퍼레이션즈 피티와이 엘티디 카나비스 조성물
CA3052564A1 (en) * 2017-02-05 2018-08-09 CannTab Therapeutics Limited Flash-melt cannabinoid formulations
US10772837B2 (en) * 2017-03-16 2020-09-15 CannTab Therapeutics, Ltd Modified release multi-layer tablet cannabinoid formulations
JP2020520966A (ja) * 2017-05-22 2020-07-16 ジービーエス グローバル バイオファーマ,インコーポレイテッド Trpv1を標的にするミルセン及びカンナビノイド含有組成物
JP2021513566A (ja) * 2018-02-09 2021-05-27 ニュートリスキ インターナショナル インク.Neutrisci International Inc. スチルベノイドとカンナビノイドとの共結晶を含む組成物

Also Published As

Publication number Publication date
MX2021012712A (es) 2021-11-12
JP7556882B2 (ja) 2024-09-26
EP4268815A3 (en) 2024-02-21
EP3920891B1 (en) 2024-02-21
ZA202107389B (en) 2025-04-30
CN113784704A (zh) 2021-12-10
PL3920891T3 (pl) 2024-05-20
ES2975266T3 (es) 2024-07-04
EP4268815A2 (en) 2023-11-01
AU2020258631B2 (en) 2023-11-02
FI3920891T3 (fi) 2024-03-19
AU2020258631A1 (en) 2021-10-28
DK3920891T3 (da) 2024-03-18
JP2022529037A (ja) 2022-06-16
WO2020211915A1 (en) 2020-10-22
EP3920891A1 (en) 2021-12-15

Similar Documents

Publication Publication Date Title
MX2021012712A (es) Tabletas de cannabinoides de desintegracion rapida.
CO6400186A2 (es) Tabletas de acetato de ulipristal
CL2008003827A1 (es) Composicion para tabletas de desintegracion oral que comprende al menos una droga ( temazepam), 0,5-3% de un polimero aglutinanete para odt, un alcohol de azucar y/o sacarido, y un desintegrante; metodo para prepararla; util para tratar una enfermedad o condicion como un trastorno del sueño en pacientes con disfagia..
BR112015029616A2 (pt) forma de dosagem resistente à adulteração com perfil de liberação bimodal
BR112015032559A8 (pt) cerâmica odontológica de zircônia, artigo odontológico, e seu método de fabricação
ES2199061B1 (es) Comprimidos bucodispersables y procedimiento para su obtencion.
Tang Sirtuins as modifiers of Parkinson's disease pathology
MX2019005827A (es) Vehiculo de suministro oral.
Deledda et al. Mitochondrial aging and senolytic natural products with protective potential
BRPI0812064B8 (pt) formulação farmacêutica na forma de aglomerados, comprimidos, e, processo para a produção de uma formulação farmacêutica
CO5190672A1 (es) Composicion para la dosificacion oral, de disolucion instantanea
MX390994B (es) Composicion nutricional que contiene mezcla de oligosacaridos.
BRPI0519212A2 (pt) composiÇÕes farmacÊuticas de desintegraÇço oral contendo agentes de manifestaÇço sensorial
BR112013009153A2 (pt) formulação de ligante de fosfato para dosagem única.
BRPI0515645A (pt) métodos terapêuticos, composições, compostos e usos de compostos
BRPI0610786B8 (pt) uso de um ou mais oligossacarídeos ácidos e neutros, e cisteína e/ou fonte de cisteína, e, composição alimentícia
BR112014026439A2 (pt) comprimidos revestidos e produção dos mesmos
AR013739A1 (es) Composiciones de agentes reductores de lipidos
Jung et al. Ecklonia cava extract exerts anti-inflammatory effect in human gingival fibroblasts and chronic periodontitis animal model by suppression of pro-inflammatory cytokines and chemokines
BR112012026714A2 (pt) pastilhas de eritritol e isomalte
BRPI0801239A2 (pt) uso de um ou mais benzopiranonas, composição farmacêutica e método de prevenção ou tratamento de doenças, disfunções e distúrbios associados a monoamino oxidase
BRPI0821454B8 (pt) formulação farmacêutica, mistura de glicogênio, alginato e sais de metais alcalino terrosos, processos para a produção de um excipiente de liberação lenta, e de uma forma farmacêutica
BR112022021602A2 (pt) Embalagem flowpack para entrega oral de ingredientes ativos
BR112017016794A2 (pt) microcápsulas que conferem nota de odor intenso de baunilha
BR112013002832A2 (pt) composição compreendendo retinol, um precursor ou um produto de reação do mesmo e um extrato vegetal de pelo menos uma planta de camomila para o tratamento de câncer

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]